Treatment of the optImuM Dose of calcineUrin Inhibitor and Mycophenolate Sodium in Kidney Recipients
Status:
Completed
Trial end date:
2016-11-30
Target enrollment:
Participant gender:
Summary
To clarify that tacrolimus-sparing regimen with minimal tacrolimus dose together with
mycophenolate sodium dose increment will preserve renal allograft function without rising
adverse effects
Primary endpoints:
1. estimated GFR (MDRD equation) 12 months after randomization
2. estimated GFR change from randomization to end of the study (calculated by MDRD equation
and Nankivell equation)
Phase:
Phase 4
Details
Lead Sponsor:
Asan Medical Center
Collaborators:
Samsung Medical Center Seoul National University Hospital